These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Aamodt WW; Waligorska T; Shen J; Tropea TF; Siderowf A; Weintraub D; Grossman M; Irwin D; Wolk DA; Xie SX; Trojanowski JQ; Shaw LM; Chen-Plotkin AS Mov Disord; 2021 Dec; 36(12):2945-2950. PubMed ID: 34480363 [TBL] [Abstract][Full Text] [Related]
26. Plasma neurofilament light chain levels in Alzheimer's disease. Zhou W; Zhang J; Ye F; Xu G; Su H; Su Y; Zhang X; Neurosci Lett; 2017 May; 650():60-64. PubMed ID: 28428015 [TBL] [Abstract][Full Text] [Related]
27. Association between plasma CTRPs with cognitive impairment and neurodegeneration of Alzheimer's disease. Huang X; Zhao J; Wang Q; Yan T; Gou S; Zhu X; Yang L; Ye F; Zhang J; Wang Y; Yang S; Le W; Xiang Y CNS Neurosci Ther; 2024 Feb; 30(2):e14606. PubMed ID: 38334009 [TBL] [Abstract][Full Text] [Related]
28. Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI. Bangen KJ; Thomas KR; Weigand AJ; Edmonds EC; Clark AL; Solders S; Delano-Wood L; Galasko DR; Bondi MW; Alzheimers Dement; 2021 Oct; 17(10):1756-1762. PubMed ID: 33860596 [TBL] [Abstract][Full Text] [Related]
29. Serum neurofilament light chain level as a predictor of cognitive stage transition. Lee EH; Kwon HS; Koh SH; Choi SH; Jin JH; Jeong JH; Jang JW; Park KW; Kim EJ; Kim HJ; Hong JY; Yoon SJ; Yoon B; Kang JH; Lee JM; Park HH; Ha J Alzheimers Res Ther; 2022 Jan; 14(1):6. PubMed ID: 34996525 [TBL] [Abstract][Full Text] [Related]
30. Plasma neurofilament light chain associated with impaired regional cerebral blood flow in healthy individuals. Nabizadeh F; Ward RT; Balabandian M; Kankam SB; Pourhamzeh M Curr J Neurol; 2023 Oct; 22(4):221-230. PubMed ID: 38425361 [No Abstract] [Full Text] [Related]
31. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Verberk IMW; Laarhuis MB; van den Bosch KA; Ebenau JL; van Leeuwenstijn M; Prins ND; Scheltens P; Teunissen CE; van der Flier WM Lancet Healthy Longev; 2021 Feb; 2(2):e87-e95. PubMed ID: 36098162 [TBL] [Abstract][Full Text] [Related]
32. Plasma Neurofilament Light Chain May Be a Biomarker for the Inverse Association Between Cancers and Neurodegenerative Diseases. Liu S; Huang Z; Zhang L; Pan J; Lei Q; Meng Y; Li Z Front Aging Neurosci; 2020; 12():10. PubMed ID: 32082140 [TBL] [Abstract][Full Text] [Related]
33. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. Sugarman MA; Zetterberg H; Blennow K; Tripodis Y; McKee AC; Stein TD; Martin B; Palmisano JN; Steinberg EG; Simkin I; Budson AE; Killiany R; O'Connor MK; Au R; Qiu WWQ; Goldstein LE; Kowall NW; Mez J; Stern RA; Alosco ML Neurobiol Aging; 2020 Oct; 94():60-70. PubMed ID: 32585491 [TBL] [Abstract][Full Text] [Related]
34. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease. Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152 [TBL] [Abstract][Full Text] [Related]
35. Combination of plasma amyloid beta Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409 [TBL] [Abstract][Full Text] [Related]
36. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. Chatterjee P; Zetterberg H; Goozee K; Lim CK; Jacobs KR; Ashton NJ; Hye A; Pedrini S; Sohrabi HR; Shah T; Asih PR; Dave P; Shen K; Taddei K; Lovejoy DB; Guillemin GJ; Blennow K; Martins RN J Neuroinflammation; 2019 Oct; 16(1):186. PubMed ID: 31601232 [TBL] [Abstract][Full Text] [Related]
37. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease. Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574 [TBL] [Abstract][Full Text] [Related]
38. Interactions Between Weight Loss and Plasma Neurodegenerative Markers for Determining Cognitive Decline Among Community-Dwelling Older Adults. Giudici KV; Guyonnet S; Morley JE; Nguyen AD; Aggarwal G; Parini A; Li Y; Bateman RJ; Vellas B; de Souto Barreto P; J Gerontol A Biol Sci Med Sci; 2022 Jun; 77(6):1159-1168. PubMed ID: 35034116 [TBL] [Abstract][Full Text] [Related]
39. Elevated Levels of Serum Neurofilament Light Chain Associated with Cognitive Impairment in Vascular Dementia. Ma W; Zhang J; Xu J; Feng D; Wang X; Zhang F Dis Markers; 2020; 2020():6612871. PubMed ID: 33204362 [TBL] [Abstract][Full Text] [Related]
40. Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. Baldacci F; Lista S; Manca ML; Chiesa PA; Cavedo E; Lemercier P; Zetterberg H; Blennow K; Habert MO; Potier MC; Dubois B; Vergallo A; Hampel H; ; Alzheimers Res Ther; 2020 Nov; 12(1):147. PubMed ID: 33183357 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]